AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)

被引：2
|
作者：
Winthrop, Kevin [1 ]
Morimoto, Kozo [1 ]
Castellotti, Paola Francesca [1 ]
Yim, Jae-Joon [1 ]
Ruoss, Stephen [1 ]
van Ingen, Jakko [1 ]
Coulter, Christopher [1 ]
Mange, Kevin [1 ]
Nezamis, James [1 ]
Griffith, David [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
CHEST | 2019年 / 156卷 / 04期
关键词：
D O I：
10.1016/j.chest.2019.08.224
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：146A / 147A
页数：2
相关论文
共 50 条
  • [21] Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease
    Marras, Theodore K.
    Hassan, Mariam
    Mange, Kevin C.
    Ciesielska, Monika
    Murthy, Shilpa Dhar
    Jumadilova, Zhanna
    Chatterjee, Anjan
    [J]. ERJ OPEN RESEARCH, 2022, 8 (03)
  • [22] A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
    Griffith, David
    Flume, Patrick
    Winthrop, Kevin
    Thomson, Rachel
    Wagner, Dirk
    Van Ingen, Jakko
    Micioni, Liza
    McGinnis, John P., II
    Fernandez, Carlos
    Eagle, Gina
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [23] Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease
    Siegel, S.
    Clock, J. A.
    Hoeft, J.
    Chan, B.
    Sullivan, P. E.
    Philley, J.
    Strnad, L. C.
    Griffith, D. E.
    Winthrop, K. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [24] Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease
    Siegel, S.
    Clock, J. A.
    Hoeft, J.
    Chan, B.
    Sullivan, P.
    Philley, J.
    Strnad, L. C.
    Griffith, D. E.
    Winthrop, K. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [25] Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Sae Rom
    Jhun, Byung Woo
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (02) : 202 - 205
  • [26] Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease
    Yanagihara, Toyoshi
    Ogata, Hiroaki
    Mori, Asami
    Kadowaki, Masako
    Moriuchi, Yuki
    Ishimatsu, Akiko
    Otsuka, Junji
    Taguchi, Kazuhito
    Moriwaki, Atushi
    Yoshida, Makoto
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [27] Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
    Urabe, Naohisa
    Sakamoto, Susumu
    Tokita, Nozomi
    Yoshida, Hiromichi
    Usui, Yusuke
    Shimizu, Hiroshige
    Sekiya, Muneyuki
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Isobe, Kazutoshi
    Kishi, Kazuma
    [J]. BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [28] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 277 - 287
  • [29] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (02) : 277 - 287
  • [30] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use (vol 41, pg 405, 2021)
    Hoy, Sheridan M.
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 591 - 591
12345